Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Biliary Tract Diseases

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 105 articles:
HTML format



Single Articles


    November 2022
  1. VILLARD C, Friis-Liby I, Rorsman F, Said K, et al
    Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03303-7. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available


  2. MERTERS J, Lamarca A
    Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03296.
    PubMed     Abstract available


    October 2022
  3. SPOSITO C, Ratti F, Cucchetti A, Ardito F, et al
    Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node negative intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Oct 31. pii: S0168-8278(22)03158.
    PubMed     Abstract available


  4. NEVENS F, Trauner M, Manns MP
    Primary biliary cholangitis as a roadmap for the development of novel treatments of cholestatic liver diseases.
    J Hepatol. 2022 Oct 19. pii: S0168-8278(22)03143.
    PubMed     Abstract available


  5. OKAWA Y, Iwasaki Y, Johnson TA, Ebata N, et al
    Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    J Hepatol. 2022 Oct 12. pii: S0168-8278(22)03137.
    PubMed     Abstract available


  6. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed    


    September 2022
  7. CONBOY CB, Yonkus JA, Buckarma EH, Mun DG, et al
    LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
    J Hepatol. 2022 Sep 23. pii: S0168-8278(22)03121.
    PubMed     Abstract available


  8. HARDING JJ, Khalil DN, Fabris L, Abou-Alfa GK, et al
    Rational Development of Combination Therapies in Biliary Tract Cancers.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03078.
    PubMed     Abstract available


  9. ARECHEDERRA M, Fernandez-Barrena MG
    Hepatic progenitor cells, senescence and IL6 as the main players in combined hepatocellular-cholangiocarcinoma development.
    J Hepatol. 2022 Sep 20. pii: S0168-8278(22)03114.
    PubMed    


  10. BJORKSTROM NK
    Immunobiology of the biliary tract system.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03020.
    PubMed     Abstract available


    August 2022
  11. ZHANG R, Huang J, Shan J, Chen Y, et al
    Peripheral blood CD177(+) cells as an early diagnostic marker for biliary atresia: a prospective multicentre study in pediatric patients with cholestasis.
    J Hepatol. 2022 Aug 19. pii: S0168-8278(22)03005.
    PubMed    


  12. ROSENBERG N, Van Haele M, Lanton T, Brashi N, et al
    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL6 trans-signaling.
    J Hepatol. 2022 Aug 18. pii: S0168-8278(22)02995.
    PubMed     Abstract available


  13. KENNEDY L, Carpino G, Owen T, Ceci L, et al
    Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02999.
    PubMed     Abstract available


  14. CALDERARO J, Di Tommaso L, Maille P, Beaufrere A, et al
    Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
    J Hepatol. 2022 Aug 17. pii: S0168-8278(22)02983.
    PubMed     Abstract available


  15. VITHAYATHIL M, Khan SA
    Current epidemiology of cholangiocarcinoma in western countries.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02988.
    PubMed     Abstract available


  16. BOWLUS CL, Levy C, Hirschfield GM
    Reply to: "Seladelpar in patients with primary biliary cholangitis: Need for a closer look!"
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02990.
    PubMed    


    July 2022
  17. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    PubMed    


  18. ZHANG R, Su L, Fu M, Wang Z, et al
    CD177(+) cells produce neutrophil extracellular traps to promote biliary atresia.
    J Hepatol. 2022 Jul 5. pii: S0168-8278(22)00409.
    PubMed     Abstract available


  19. MULLER AL, Casar C, Preti M, Krzikalla D, et al
    Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02923.
    PubMed     Abstract available


    June 2022
  20. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    PubMed     Abstract available


  21. HUANG B, Lyu Z, Qian Q, Chen Y, et al
    NUDT1 promotes the accumulation and longevity of CD103(+) TRM cells in primary biliary cholangitis.
    J Hepatol. 2022 Jun 23. pii: S0168-8278(22)00408.
    PubMed     Abstract available


  22. LABIANO I, Agirre-Lizaso A, Olaizola P, Echebarria A, et al
    TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.
    J Hepatol. 2022 Jun 21. pii: S0168-8278(22)00372.
    PubMed     Abstract available


  23. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    PubMed     Abstract available


  24. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    PubMed    


  25. HOGDALL D, O'Rourke CJ, Larsen FO, Zarforoushan S, et al
    Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00358.
    PubMed     Abstract available


  26. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    PubMed    


  27. SCHLEGEL A, Porte R, Dutkowski P
    Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy.
    J Hepatol. 2022;76:1330-1347.
    PubMed     Abstract available


    May 2022

  28. EASL Clinical Practice Guidelines on Sclerosing Cholangitis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00326.
    PubMed    


  29. MISHRA AK, Singh SP
    Seladelpar in patients with primary biliary cholangitis: Need a closer look!
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00315.
    PubMed    


  30. RAGGI C, Taddei ML, Rae C, Braconi C, et al
    Metabolic Reprogramming in Cholangiocarcinoma.
    J Hepatol. 2022 May 17. pii: S0168-8278(22)00314.
    PubMed     Abstract available


  31. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    PubMed    


    April 2022
  32. LUDDE T, Boulter L
    Joining the dots - NEDDylation in cancer cells regulates the tumour environment in Cholangiocarcinoma.
    J Hepatol. 2022 Apr 28. pii: S0168-8278(22)00253.
    PubMed    


    March 2022
  33. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    PubMed     Abstract available


  34. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    PubMed     Abstract available


  35. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    PubMed    


    February 2022
  36. OLAIZOLA P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, et al
    Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00082.
    PubMed     Abstract available


  37. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    PubMed     Abstract available


    January 2022
  38. CASOLINO R, Amato F, Rae C, Puttagunta S, et al
    Receptor Tyrosine kinase co-amplification and benefit from HER2 inhibitors in Biliary Tract Cancers.
    J Hepatol. 2022 Jan 27. pii: S0168-8278(22)00025.
    PubMed    


    December 2021
  39. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    PubMed     Abstract available


  40. IZQUIERDO-SANCHEZ L, Lamarca A, La Casta A, Buettner S, et al
    Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02252.
    PubMed     Abstract available


  41. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    PubMed    


    November 2021
  42. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    PubMed     Abstract available


    October 2021
  43. HERTA T, Kersten R, Chang JC, Hubers L, et al
    Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection.
    J Hepatol. 2021 Oct 27. pii: S0168-8278(21)02116.
    PubMed     Abstract available


  44. KEPPLER D, Beuers U, Trauner M
    A life with bile acids: Alan F. Hofmann (1931-2021).
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02081.
    PubMed    


  45. LOUIS C, Coulouarn C
    One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/beta-catenin pathways in cholangiocarcinoma.
    J Hepatol. 2021 Oct 12. pii: S0168-8278(21)02108.
    PubMed    


  46. MALLET V
    Reply to: "Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered".
    J Hepatol. 2021;75:990-992.
    PubMed    


    September 2021
  47. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    PubMed     Abstract available


  48. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    PubMed     Abstract available


    August 2021
  49. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
    New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
    J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
    PubMed    


  50. DE JONG IEM, van den Heuvel MC, Wells RG, Porte RJ, et al
    The heterogeneity of the biliary tree.
    J Hepatol. 2021 Aug 19. pii: S0168-8278(21)00251.
    PubMed    


    July 2021
  51. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    PubMed     Abstract available


  52. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
    AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
    PubMed    


  53. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    PubMed    


    June 2021
  54. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    PubMed     Abstract available


  55. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    PubMed    


  56. ZHANG Y, Zuo C, Liu L, Hu Y, et al
    Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00442.
    PubMed     Abstract available


  57. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    PubMed    


  58. WEI G, Cao J, Huang P, An P, et al
    Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
    J Hepatol. 2021;74:1416-1428.
    PubMed     Abstract available


    May 2021
  59. SONG X, Xu H, Wang P, Wang J, et al
    Focal Adhesion Kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00353.
    PubMed     Abstract available


  60. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    PubMed     Abstract available


  61. BOULTER L, Ebrahimkhani MR
    Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
    J Hepatol. 2021 May 21. pii: S0168-8278(21)00341.
    PubMed    


  62. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    PubMed    


  63. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    PubMed     Abstract available


    April 2021
  64. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    PubMed     Abstract available


  65. REICH M, Spomer L, Klindt C, Fuchs K, et al
    Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00244.
    PubMed     Abstract available


  66. VALLEJO A, Erice O, Entrialgo-Cadierno R, Feliu I, et al
    FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
    J Hepatol. 2021 Apr 14. pii: S0168-8278(21)00235.
    PubMed     Abstract available


    March 2021
  67. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    PubMed     Abstract available


  68. DELTENRE P, Moreno C, Trepo E
    Progressive cholangiopathy in Covid-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.
    J Hepatol. 2021 Mar 19. pii: S0168-8278(21)00179.
    PubMed    


  69. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    PubMed     Abstract available


  70. CRISTINZIANO G, Porru M, Lamberti D, Buglioni S, et al
    FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    J Hepatol. 2021 Mar 16. pii: S0168-8278(21)00172.
    PubMed     Abstract available


  71. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
    Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
    J Hepatol. 2021;74:593-602.
    PubMed     Abstract available


    February 2021
  72. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    PubMed    


  73. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    PubMed    


  74. BOYER JL, Soroka CJ
    Bile formation and Secretion: An update.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00111.
    PubMed     Abstract available


  75. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    PubMed    


  76. CASOLINO R, Braconi C
    CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00045.
    PubMed    


  77. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    PubMed    


  78. ROESSLER S, Edeline J, Schirmacher P, Coulouarn C, et al
    Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer.
    J Hepatol. 2021 Feb 16. pii: S0168-8278(21)00007.
    PubMed    


  79. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    PubMed    


  80. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    PubMed     Abstract available


  81. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    PubMed     Abstract available


    January 2021
  82. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    PubMed     Abstract available


  83. JAVITT NB
    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
    PubMed    


  84. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    PubMed     Abstract available


  85. RAGGI C, Taddei ML, Sacco E, Navari N, et al
    Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00024.
    PubMed     Abstract available


  86. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    PubMed     Abstract available


  87. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    PubMed    


  88. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    PubMed    


    December 2020
  89. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
    PubMed    


  90. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
    PubMed    


  91. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    PubMed     Abstract available


  92. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    PubMed     Abstract available


  93. NEPAL C, Zhu B, O'Rourke CJ, Bhatt DK, et al
    Integrative molecular characterization of gallbladder cancer reveals microenvironment-associated subtypes.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33820.
    PubMed     Abstract available


    November 2020
  94. DWYER BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, et al
    TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33771.
    PubMed     Abstract available


  95. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    PubMed     Abstract available


  96. STEIN S, Henze L, Poch T, Carambia A, et al
    IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33759.
    PubMed     Abstract available


    October 2020
  97. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    PubMed     Abstract available


  98. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    PubMed    


  99. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    PubMed    


  100. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    PubMed     Abstract available


    September 2020
  101. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    PubMed    


    July 2020
  102. TRAUNER M
    Effective medical treatments for PSC needed ASAP - is AESOP the answer?
    J Hepatol. 2020;73:12-14.
    PubMed    


    June 2020
  103. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    PubMed    


  104. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    PubMed    


    April 2020
  105. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: